Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)

Next Previous
Search
Trial Profile

An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon alfa-2a (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis D
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms LOWR HDV-1; LOWR-1
  • Sponsors Eiger BioPharmaceuticals

    • Most Recent Events

    • 14 Nov 2023 Results analyzing interplay between HDV RNA, HBV DNA AND HBsAg during LONAFARNIB based therapy via mathematical modeling, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
    • 08 Nov 2022 Results of retrospective study (n=5; from Phase 2 LOWR 1 and LOWR 2 studies) assessing the effect of oral LNF based therapy of 3 to 12 months duration with long term follow up delineating durable off treatment biochemical and viral efficacy presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
    • 20 Nov 2017 Primary endpoint (Mean HDV viral load decline after 4 weeks of treatment with lonafarnib therapy (monotherapy or as combination therapy)) has been met, according to results published in the Hepatology Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top